Wall Street Zen Upgrades Quantum Biopharma (NASDAQ:QNTM) to “Hold”

Quantum Biopharma (NASDAQ:QNTM) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Quantum Biopharma Price Performance

NASDAQ QNTM opened at $15.45 on Friday. Quantum Biopharma has a one year low of $2.70 and a one year high of $18.00. The firm has a market cap of $41.81 million, a P/E ratio of -1.00 and a beta of 0.55. The stock’s 50-day moving average is $9.08 and its 200-day moving average is $6.58.

Quantum Biopharma (NASDAQ:QNTM) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($1.04). The business had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $2.09 million. Equities analysts anticipate that Quantum Biopharma will post -3.27 EPS for the current year.

Institutional Trading of Quantum Biopharma

A hedge fund recently raised its stake in Quantum Biopharma stock. AdvisorShares Investments LLC boosted its position in Quantum Biopharma Ltd. (NASDAQ:QNTM) by 163.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 69,078 shares of the company’s stock after buying an additional 42,845 shares during the quarter. AdvisorShares Investments LLC owned approximately 3.60% of Quantum Biopharma worth $254,000 as of its most recent filing with the SEC. Institutional investors own 1.24% of the company’s stock.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.